{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:13:03Z","timestamp":1790039583144,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ijantimicag.2019.09.012","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T11:35:54Z","timestamp":1568806554000},"page":"697-701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-0139","authenticated-orcid":false,"given":"Giuseppina","family":"Brancaccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1573-6224","authenticated-orcid":false,"given":"Giovanni B.","family":"Gaeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0002","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","author":"Chen","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0003","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jhep.2009.01.004","article-title":"Hepatitis delta: thirty years after","volume":"50","author":"Rizzetto","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0004","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/liv.13604","article-title":"Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: the Hepatitis Delta International Network (HDIN)","volume":"38","author":"Wranke","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0005","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1053\/jhep.2000.17711","article-title":"Chronic hepatitis D: a vanishing disease? An Italian multicenter study","volume":"32","author":"Gaeta","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0006","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/hep.21816","article-title":"Hepatitis delta in Europe: vanishing or refreshing?","volume":"46","author":"Gaeta","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0007","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/jmv.21078","article-title":"The increasing prevalence of hepatitis delta virus (HDV) infection in south London","volume":"80","author":"Cross","year":"2008","journal-title":"J Med Virol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0008","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/hep.21590","article-title":"Hepatitis D virus infection\u2014not a vanishing disease in Europe!","volume":"45","author":"Wedemeyer","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0009","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.dld.2018.09.008","article-title":"The present profile of chronic hepatitis B virus infection highlights future challenges: an analysis of the multicenter Italian MASTER-B cohort","volume":"51","author":"Brancaccio","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3851\/IMP2598","article-title":"An update on HDV: virology, pathogenesis and treatment","volume":"18","author":"Alvarado-Mora","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0011","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-8278(85)80766-2","article-title":"Delta hepatitis\u2014present status","volume":"1","author":"Rizzetto","year":"1985","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0012","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/hep.20944","article-title":"Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus\/hepatitis C virus-coinfected patients","volume":"43","author":"Raimondo","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0013","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jhep.2009.10.036","article-title":"Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D","volume":"52","author":"Schaper","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0014","doi-asserted-by":"crossref","first-page":"7951","DOI":"10.1128\/JVI.79.13.7951-7958.2005","article-title":"RNA replication without RNA-dependent RNA polymerase: surprises from hepatitis delta virus","volume":"79","author":"Lai","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0032-1323623","article-title":"Virology of hepatitis D virus","volume":"32","author":"Taylor","year":"2012","journal-title":"Semin Liver Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2019.09.012_bib0016","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.jhep.2016.02.013","article-title":"The hepatitis delta virus: replication and pathogenesis","volume":"64","author":"Sureau","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0017","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0018","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jhep.2008.05.029","article-title":"Complete cure of HBV\u2013HDV co-infection after 24 weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV\/HCV\/HDV\/HIV","volume":"50","author":"Gozlan","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0019","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2018.12.022","article-title":"Treating chronic hepatitis delta: the need of surrogate markers of treatment efficacy","volume":"70","author":"Yurdaydin","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0020","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/hep.28772","article-title":"International external quality assessment of hepatitis delta virus RNA quantification in plasma","volume":"64","author":"Le Gal","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0021","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0022","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/infdis\/jix656","article-title":"Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease","volume":"217","author":"Yurdaydin","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0023","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.28876","article-title":"Antiviral treatment and liver-related complications in hepatitis delta","volume":"65","author":"Wranke","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0024","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0025","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2013.07.005","article-title":"Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study","volume":"59","author":"Manesis","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0026","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2010.06.008","article-title":"Outcome of chronic delta hepatitis in Italy: a long-term cohort study","volume":"53","author":"Niro","year":"2010","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.ijantimicag.2019.09.012_bib0027","article-title":"Interferon alpha for chronic hepatitis D","author":"Abbas","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0028","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","article-title":"Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up","volume":"44","author":"Castelnau","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0029","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"Niro","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0030","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1478-3231.2006.01279.x","article-title":"Treatment of chronic hepatitis delta with pegylated interferon-alpha2b","volume":"26","author":"Erhardt","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0031","first-page":"377","article-title":"Weight-based dosing regimen of peg-interferon \u03b1-2b for chronic hepatitis delta: a multicenter Romanian trial","volume":"20","author":"Gheorghe","year":"2011","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0032","first-page":"1648","article-title":"Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months","volume":"58","author":"Ormeci","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0033","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0034","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.3748\/wjg.v18.i40.5793","article-title":"Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response","volume":"18","author":"Samiullah","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0035","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3851\/IMP2381","article-title":"Efficacy of pegylated interferon-\u03b1 treatment for 24 months in chronic delta hepatitis and predictors of response","volume":"18","author":"Karaca","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0036","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0037","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12788","article-title":"Long-term therapy of chronic delta hepatitis with peginterferon alfa","volume":"40","author":"Heller","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0038","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijid.2016.03.017","article-title":"Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir","volume":"46","author":"Borzacov","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0039","doi-asserted-by":"crossref","first-page":"e24366","DOI":"10.5812\/hepatmon.24366","article-title":"Pegylated interferon \u03b1 therapy in chronic delta hepatitis: a one-center experience","volume":"15","author":"Bahcecioglu","year":"2015","journal-title":"Hepat Mon"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0040","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/infdis\/jix656","article-title":"Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease","volume":"217","author":"Yurdaydin","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0041","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0042","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/apt.13734","article-title":"HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response","volume":"44","author":"Niro","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0043","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.cgh.2015.05.029","article-title":"Association between level of hepatitis D virus RNA at Week 24 of pegylated interferon therapy and outcome","volume":"13","author":"Keskin","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0044","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/jvh.12947","article-title":"Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy","volume":"25","author":"Lutterkort","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0045","doi-asserted-by":"crossref","unstructured":"Ricco G., Popa D.C., Cavallone D., Iacob S., Salvati A., Tabacelia D., et al. Quantification of serum markers of hepatitis B (HBV) and delta virus (HDV) infections in patients with chronic HDV infection J Viral Hepat2018;25:911\u20139.","DOI":"10.1111\/jvh.12895"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0046","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2036.2005.02542.x","article-title":"Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study","volume":"22","author":"Niro","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0047","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1440-1746.2006.04082.x","article-title":"Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial","volume":"21","author":"Canbakan","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0048","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2893.2007.00936.x","article-title":"Treatment of chronic delta hepatitis with lamivudine vs lamivudine\u202f+\u202finterferon vs interferon","volume":"15","author":"Yurdaydin","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0049","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/cid\/cis459","article-title":"Entecavir treatment of chronic hepatitis D","volume":"55","author":"Kaba\u00e7am","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0050","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4254\/wjh.v8.i14.625","article-title":"Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: a randomized trial","volume":"8","author":"Abbas","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0051","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/apt.15188","article-title":"Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir","volume":"49","author":"Brancaccio","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0052","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0053","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.3390\/molecules15074773","article-title":"Solid-phase synthesis of the lipopeptide Myr-HBVpreS\/2-78, a hepatitis B virus entry inhibitor","volume":"15","author":"Schieck","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0054","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2019.09.012_bib0055","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","article-title":"Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of myrcludex B in combination with tenofovir in patients with chronic HBV\/HDV infection","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0056","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2019.07.003","article-title":"Excellent safety and effectiveness of high-dose myrcludex-b monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: a case report of 3 patients","volume":"71","author":"Loglio","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0057","doi-asserted-by":"crossref","first-page":"10465","DOI":"10.1128\/JVI.76.20.10465-10472.2002","article-title":"A prenylation inhibitor prevents production of infectious hepatitis delta virus particles","volume":"76","author":"Bordier","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0058","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1172\/JCI17704","article-title":"In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus","volume":"112","author":"Bordier","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0059","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial","volume":"15","author":"Koh","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0060","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0061","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2016.07.004","article-title":"Nucleic acid polymers: broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection","volume":"133","author":"Vaillant","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0062","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/hep.29737","article-title":"Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks","volume":"67","author":"Quinet","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0063","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomized, open label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0064","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1038\/s41598-017-03946-9","article-title":"Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV\/HDV infected humanized mice","volume":"7","author":"Giersch","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2019.09.012_bib0065","first-page":"496A","article-title":"A phase 2 randomized clinical trial to evaluate the safety and efficacy of pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection","volume":"66","author":"Hamid","year":"2017","journal-title":"Interim results from the LIMT HDV Study (abstract). Hepatology"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919302559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919302559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:33:13Z","timestamp":1760376793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919302559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0924857919302559"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.09.012","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}